Predictors of Radiotherapy-related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of NRG Oncology RTOG 0529

Jeffrey Olsen, MD1, Jennifer Moughan, MS2, Robert Myerson, MD, PhD3, Andre Abitbol, MD4, Desiree E Doncals, MD5, Douglas Johnson, MD6, Tracey E. Schefter, MD1, Yuhchyau Chen, MD, PhD7, Barbara Fisher, MD8, Jeff Michalski, MD3, Samir Narayan, MD9, Albert Chang, MD, PhD10, Christopher H. Crane, MD11, and Lisa Kachnic, MD12 1University of Colorado Denver, Denver, CO 2NRG Oncology Statistics and Data Management Center, Philadelphia, PA 3Washington University, St. Louis, MO 4Baptist Hospital of Miami, Miami, FL 5Summa Akron City Hospital accruals for Akron City Hospital, Akron, OH 6Florida Radiation Oncology Group – Baptist Regional, Jacksonville, FL 7University of Rochester Medical Center, Rochester, NY 8London Regional Cancer Program — University of Western Ontario, London, ON 9Michigan Cancer Research Consortium CCOP, Ann Arbor, MI 10University of California San Francisco, San Francisco, CA 11Memorial Sloan Kettering Cancer Center, New York, NY 12Vanderbilt University Medical Center, Nashville, TN

[1]  D. Heron,et al.  Dosimetric Parameters Predictive of Acute Gastrointestinal Toxicity in Patients with Anal Carcinoma Treated with Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy , 2013, Oncology.

[2]  Jacqueline Esthappan,et al.  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2013, International journal of radiation oncology, biology, physics.

[3]  Issam El Naqa,et al.  Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. , 2012, International journal of radiation oncology, biology, physics.

[4]  A. Bennett,et al.  Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. , 2012, Gastrointestinal cancer research : GCR.

[5]  Ronald C. Chen,et al.  Patient‐reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer , 2010, Cancer.

[6]  Per Nilsson,et al.  The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay , 2009, Radiation oncology.

[7]  J. Roeske,et al.  A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Issam El Naqa,et al.  Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. , 2009, International journal of radiation oncology, biology, physics.

[9]  Charles R. Thomas,et al.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. , 2008, JAMA.

[10]  D. Yan,et al.  The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. , 2008, International journal of radiation oncology, biology, physics.

[11]  P. Bendahl,et al.  Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer , 2007, Acta oncologica.

[12]  L. Tho,et al.  Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. , 2006, International journal of radiation oncology, biology, physics.

[13]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[14]  H. Bartelink,et al.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. James.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin , 1996, The Lancet.

[16]  N. Petrelli,et al.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Yan,et al.  The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[18]  V. Vaitkevicius,et al.  Combined therapy for cancer of the anal canal: A preliminary report , 1974, Diseases of the colon and rectum.

[19]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.